Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943597 | 0.90 | GRIN2B (0.45) | GRIN2BHTR7SIGMAR1NCF1NPY2R | |
| SCHEMBL932530 | 0.89 | GRIN2B (0.44) | GRIN2BHTR7SIGMAR1SRPK1NCF1 | |
| SCHEMBL13020353 | 0.88 | NCF1 (0.45) | GRIN2BALDH1A1LMNASRPK1NCF1 | |
| SCHEMBL931032 | 0.85 | — | — | |
| SCHEMBL932185 | 0.83 | PRMT1 (0.57) | ALDH1A1LMNA | |
| SCHEMBL942896 | 0.74 | KMT2A (0.43) | SRPK1NCF1NPY2R | |
| SCHEMBL7474178 | 0.72 | MEN1 (0.51) | HTR7SIGMAR1 | |
| SCHEMBL931464 | 0.71 | GRIN2B (0.67) | GRIN2BALDH1A1LMNA | |
| SCHEMBL931132 | 0.71 | HTR1A (0.54) | — | |
| SCHEMBL932222 | 0.70 | PRMT1 (0.59) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | GRIN2B 80/4885HTR7 19/4885SIGMAR1 157/4885 |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | C1R, CBR1, HTR2C | GRIN2B 50/4885HTR7 41/4885SIGMAR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.